Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23623328 | 0.93 | LMNA (0.38) | MAPTPDE5ACTSALMNATP53 | |
| SCHEMBL23758243 | 0.90 | ROCK2 (0.38) | MAPTPDE5ACTSALMNATP53 | |
| SCHEMBL23611738 | 0.89 | ALOX15 (0.44) | ALOX15HSD17B10MAPTLMNATP53 | |
| SCHEMBL23623326 | 0.88 | ALOX15 (0.41) | ALOX15HSD17B10MAPTPDE5AGPR6 | |
| SCHEMBL29930729 | 0.88 | ALOX15 (0.47) | ALOX15HSD17B10MAPTTP53NPC1 | |
| SCHEMBL23611755 | 0.88 | ALOX15 (0.47) | ALOX15HSD17B10MAPTTP53NPC1 | |
| SCHEMBL23623267 | 0.84 | TP53 (0.42) | ALOX15HSD17B10MAPTLMNATP53 | |
| SCHEMBL23611767 | 0.83 | TP53 (0.42) | ALOX15HSD17B10MAPTCTSALMNA | |
| SCHEMBL23611711 | 0.83 | ADORA3 (0.41) | ALOX15HSD17B10MAPTLMNATP53 | |
| SCHEMBL23623309 | 0.83 | ALOX15 (0.43) | ALOX15HSD17B10MAPTPDE5ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091590-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BERG LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| WO-2021138540-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | BERG LLC (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | ALOX15 3002/4885HSD17B10 828/4885MAPT 1520/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | ALOX15 3002/4885HSD17B10 828/4885MAPT 1520/4885 |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | ALOX15 3002/4885HSD17B10 828/4885MAPT 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.